Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). (Q51037967)
Jump to navigation
Jump to search
scientific article published in June 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). |
scientific article published in June 2013 |
Statements
Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). (English)
1 reference
K Reich
1 reference
G Wozel
1 reference
H Zheng
1 reference
H J F van Hoogstraten
1 reference
L Flint
1 reference
1 June 2013
1 reference
168
1 reference
6
1 reference
1325-1334
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference